Lipocalin 2 - mutation screen and serum levels in patients with anorexia nervosa or obesity and in lean individuals

Front Endocrinol (Lausanne). 2023 Mar 21:14:1137308. doi: 10.3389/fendo.2023.1137308. eCollection 2023.

Abstract

Context: The bone-derived adipokine lipocalin-2 is relevant for body weight regulation by stimulating the leptin-melanocortin pathway.

Objective: We aimed to (i) detect variants in the lipocalin-2 gene (LCN2) which are relevant for body weight regulation and/or anorexia nervosa (AN); (ii) describe and characterize the impact of LCN2 and MC4R variants on circulating lipocalin-2 level.

Methods: Sanger sequencing of the coding region of LCN2 in 284 children and adolescents with severe obesity or 287 patients with anorexia nervosa. In-silico analyses to evaluate functional implications of detected LCN2 variants. TaqMan assays for rare non-synonymous variants (NSVs) in additional independent study groups. Serum levels of lipocalin-2 were measured by ELISA in 35 females with NSVs in either LCN2 or MC4R, and 33 matched controls without NSVs in the two genes.

Results: Fourteen LCN2-variants (five NSVs) were detected. LCN2-p.Leu6Pro and p.Gly9Val located in the highly conserved signal peptide region may induce functional consequences. The secondary structure change of lipocalin-2 due to LCN2-p.Val89Ile may decrease solubility and results in a low lipocalin-2 level in a heterozygotes carrier (female recovered from AN). Lean individuals had lower lipocalin-2 levels compared to patients with obesity (p = 0.033).

Conclusion: Lipocalin-2 levels are positively associated with body mass index (BMI). Single LCN2-variants might have a profound effect on lipocalin-2 levels.

Keywords: Energy homeostasis; GWAS; bone marrow; lean body mass (LBM); secondary structure of protein.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Anorexia Nervosa* / genetics
  • Child
  • Female
  • Humans
  • Lipocalin-2* / genetics
  • Mutation
  • Obesity / metabolism
  • Obesity, Morbid*

Substances

  • Lipocalin-2
  • LCN2 protein, human

Grants and funding

This study was funded by the Deutsche Forschungsgemeinschaft (DFG; HI 865/2-1), the BMBF (01GS0820; PALGER 2017-33: 01DH19010) and the Stiftung Universitätsmedizin Essen.